---
title: "CINGULATE INC C/WTS 10/12/2026 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -1.04"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/239424967.md"
datetime: "2025-05-08T20:42:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/239424967.md)
  - [en](https://longbridge.com/en/news/239424967.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/239424967.md)
generator: "portal-rs"
---

# CINGULATE INC C/WTS 10/12/2026 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -1.04

EPS: As of FY2025 Q1, the actual value is USD -1.04.

EBIT: As of FY2025 Q1, the actual value is USD -3.803 M.

### Segment Revenue

-   **Clinical Operations**: $1,107,474 for the three months ended March 31, 2025, compared to $1,077,190 for the same period in 2024, representing a 2.9% increase.
-   **Drug Manufacturing and Formulation**: $380,353 for the three months ended March 31, 2025, compared to $341,199 for the same period in 2024, representing an 11.4% increase.

### Operational Metrics

-   **Net Loss**: $3,802,691 for the three months ended March 31, 2025, compared to $2,972,477 for the same period in 2024, representing a 28.0% increase.
-   **Operating Loss**: $3,706,035 for the three months ended March 31, 2025, compared to $2,948,217 for the same period in 2024, representing a 25.7% increase.

### Cash Flow

-   **Net Cash Used in Operating Activities**: - $4,608,282 for the three months ended March 31, 2025, compared to - $8,746,360 for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: $1,915,927 for the three months ended March 31, 2025, compared to $9,889,283 for the same period in 2024.

### Unique Metrics

-   **Stock-Based Compensation Expense**: $357,649 for the three months ended March 31, 2025, compared to $164,575 for the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to file its NDA submission for CTx-1301 in mid-2025 and believes its cash will satisfy capital needs into the fourth quarter of 2025 under the current business plan.
-   **Non-Core Business**: The company received a grant of $3 million to support the clinical and manufacturing development of CTx-2103, with payments contingent on specific milestones.

### Priority

-   The company is actively seeking strategic partnerships for licensing CTx-1301 in the United States and internationally, and has entered into a master services agreement with Indegene for commercialization services.

### Related Stocks

- [CINGW.US](https://longbridge.com/en/quote/CINGW.US.md)

## Related News & Research

- [Why is your gold waiting on a speech?](https://longbridge.com/en/news/296733808.md)
- [North Sea Crude-WTI weakens on lower offer](https://longbridge.com/en/news/296813963.md)
- [Nvidia Earnings: Wall Street Expects Growth to Slow in Q2 — Dan Niles Says Hyperscalers Are Spending Like Never Before](https://longbridge.com/en/news/296822352.md)
- [There’s More to Consider, Says Investor About Sandisk Stock](https://longbridge.com/en/news/296795615.md)
- [AMD or Nvidia: Load Up on One AI Chip Stock, but Avoid the Other, Says Investor](https://longbridge.com/en/news/296792383.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**